STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) are approved by FDA for all indications of PROLIA® (denosumab) and ...

At the Neurosurgery & Spine Group (NSG), based in Los Angeles, neurosurgeons Dr. Jared Ament and Dr. Amir Vokshoor have ...

Patient-reported outcomes could have a prognostic and predictive impact on care for multiple myeloma.A retrospective analysis ...

A study led by Cambridge researchers has shed light on how neural stem cell grafts could help restore myelin in the central ...

Panelists discuss the emotional and diagnostic journey of a multiple myeloma patient and his care partner, highlighting how ...

The FDA approved Lynozyfic (linvoseltamab-gcpt) to treat adults with relapsed/refractory multiple myeloma who have received at least 4 prior lines of therapy.

Regeneron Pharmaceuticals has received accelerated FDA approval for Lynozyfic, a new bispecific antibody treatment for adults with relapsed or refractory multiple myeloma who have undergone at least ...

A groundbreaking NHS therapy for myeloma uses a 'Trojan horse' approach to target cancer cells, offering longer remission, ...

Early detection of blood cancer can be life-saving. Here are five warning signs you must never overlook, according to an ...

Multiple myeloma causes lytic or osteolytic lesions, which are areas of damage caused by cancerous plasma cells blocking normal bone growth. While painful, they can be managed. Multiple myeloma is ...

On-body delivery systems for subcutaneous isatuximab could enable patient self-administration, according to Xavier Leleu, MD, PhD, improving convenience and transforming treatment for ...

I share how traveling fueled my passion for life, how myeloma changed my journeys, and how new mobility options have opened ...